Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

BACKGROUND. This phase II single-arm trial evaluated afatinib, an irreversible inhibitor of the ErbB receptor family as third-line treatment of Korean patients with advanced non-small cell lung cancer (NSCLC) and tumors with wild-type EGFR. Currently, no standard therapy exists for these patients. M...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ahn, Myung-Ju, Kim, Sang-We, Cho, Byoung-Chul, Ahn, Jin Seok, Lee, Dae Ho, Sun, Jong-Mu, Massey, Dan, Kim, Miyoung, Shi, Yang, Park, Keunchil
פורמט: Artigo
שפה:Inglês
יצא לאור: AlphaMed Press 2014
נושאים:
Clinical Trial Results
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077442/
https://ncbi.nlm.nih.gov/pubmed/24868099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0419
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים